(GMCR, STEM, DSCO) CRWENewswire Stocks In Action

  • Uploaded by Karmastock on Feb 2, 2012
  • Views: 329
StemCells Inc - STEM - reported that the FDA has authorized the initiation of a Phase I/II clinical trial of the Company’s proprietary HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration

StemCells Inc - STEM - reported that the FDA has authorized the initiation of a Phase I/II clinical trial of the Company’s proprietary HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration

Categories:
Show More Show Less
Comments